New hope for down syndrome vision loss: light therapy trial launches
NCT ID NCT07135167
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a treatment called corneal crosslinking (CXL) for people with Down syndrome who have keratoconus, a condition where the cornea thins and bulges, blurring vision. The procedure uses vitamin B2 eye drops and ultraviolet light to strengthen the cornea. Researchers want to see if it can slow or stop vision loss. The study will enroll 225 people aged 8 and older and follow them for 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
riboflavin (vitamin B2) eye drops and ultraviolet (UVA) light
What this could lead to
If it works, this could offer a way to slow or stop vision loss from keratoconus in people with Down syndrome, helping them keep their sight longer.
What could go wrong
This is still experimental and not FDA-approved. The study is relatively small (225 people) and only follows participants for 6 months, so long-term benefits or risks are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KERATOCONUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Woolfson Eye Institute
RECRUITINGAtlanta, Georgia, 30328, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGAtlanta, Georgia, 30349, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGCanton, Georgia, 30114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGCumming, Georgia, 30041, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGDouglasville, Georgia, 30134, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGLawrenceville, Georgia, 30043, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGMarietta, Georgia, 30066, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGSnellville, Georgia, 30078, United States
Contact Phone: •••-•••-••••
-
Woolfson Eye Institute
RECRUITINGAsheville, North Carolina, 28803, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGChattanooga, Tennessee, 37421, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Woolfson Eye Institute
RECRUITINGJohnson City, Tennessee, 37615, United States
Contact Phone: •••-•••-••••
-
Woolfson Eye Institute
RECRUITINGKnoxville, Tennessee, 37922, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••